|Bid||0.0000 x 1100|
|Ask||0.0000 x 2900|
|Day's range||2.6000 - 2.8400|
|52-week range||1.6000 - 8.7800|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.40|
LOS ANGELES, June 07, 2022--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 38,125 shares of Puma common stock to six new non-executive employees.
LOS ANGELES, June 06, 2022--Puma Biotechnology presented results from its SUMMIT Trial, Metastatic Breast Cancer, in a poster presentation at ASCO 2022.
LOS ANGELES, June 04, 2022--Puma Biotechnology presented Biliary Tract Cancer results from its SUMMIT Trial in a poster presentation at ASCO 2022.